VolitionRx Limited (NYSE American: VNRX) has entered into a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition's strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities, and installed analyzer base to accelerate development and commercialization.
According to the announcement, the collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. Volition believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring, and address a commercial opportunity with an estimated total addressable market of $3.8 billion.
Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
The collaboration with Sysmex is a significant step for Volition as it seeks to bring its Nu.Q® NETs assay to market. By partnering with a global diagnostics leader, Volition can tap into Sysmex's extensive distribution network and regulatory expertise, potentially speeding up the time to market for the assay. The optimization phase is crucial for ensuring the assay performs effectively on the Sysmex platform, which is widely used in clinical laboratories worldwide.
The implications of this announcement are far-reaching. If successful, the Nu.Q® NETs assay could revolutionize the diagnosis and monitoring of sepsis and other NETosis-related diseases. Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs, and early detection is critical for improving patient outcomes. The availability of a reliable blood test for NETosis could enable earlier intervention and better patient management.
For more details, the full press release can be accessed at https://ibn.fm/TSMG4. Additional information about Volition is available on their website at https://volition.com/.
